PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ
    Martinez, Nicholas G.
    Thieker, David F.
    Carey, Leiah M.
    Rasquinha, Juhi A.
    Kistler, Samantha K.
    Kuhlman, Brian A.
    Campbell, Sharon L.
    JOURNAL OF MOLECULAR BIOLOGY, 2021, 433 (08)
  • [32] Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
    Patel, Krish
    Pagel, John M.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (04) : 292 - 301
  • [33] Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors
    Barlaam, Bernard
    Cosulich, Sabina
    Fitzek, Martina
    Germain, Herve
    Green, Stephen
    Hanson, Lyndsey L.
    Harris, Craig S.
    Hancox, Urs
    Hudson, Kevin
    Lambert-van der Brempt, Christine
    Lamorlette, Maryannick
    Magnien, Francoise
    Ouvry, Gilles
    Page, Ken
    Ruston, Linette
    Ward, Lara
    Delouvrie, Benedicte
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 3030 - 3035
  • [34] Small-molecule inhibitors of the PI3K signaling network
    McNamara, Colleen R.
    Degterev, Alexei
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (05) : 549 - 565
  • [35] Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors
    Raj, Aditya
    Kumar, Adarsh
    Singh, Ankit Kumar
    Singh, Harshwardhan
    Thareja, Suresh
    Kumar, Pradeep
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (09) : 1013 - 1047
  • [36] Development and safety of PI3K inhibitors in cancer
    Yu, Miaomiao
    Chen, Jiajia
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    ARCHIVES OF TOXICOLOGY, 2023, 97 (03) : 635 - 650
  • [37] PI3K inhibitors: review and new strategies
    Zhang, Mingzhen
    Jang, Hyunbum
    Nussinov, Ruth
    CHEMICAL SCIENCE, 2020, 11 (23) : 5855 - 5865
  • [38] PI3K inhibitors are finally coming of age
    Vanhaesebroeck, Bart
    Perry, Matthew W. D.
    Brown, Jennifer R.
    Andre, Fabrice
    Okkenhaug, Klaus
    NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (10) : 741 - 769
  • [39] Development and safety of PI3K inhibitors in cancer
    Miaomiao Yu
    Jiajia Chen
    Zhifei Xu
    Bo Yang
    Qiaojun He
    Peihua Luo
    Hao Yan
    Xiaochun Yang
    Archives of Toxicology, 2023, 97 : 635 - 650
  • [40] PI3K signaling in Leishmania infections
    Kima, Peter E.
    CELLULAR IMMUNOLOGY, 2016, 309 : 19 - 22